Ladarixin

Generic Name: Ladarixin

Drug Type: Small Molecule

Chemical Formula: C_₁₁H_₁₂F_₃NO_₆S_₂

CAS Number: 849776-05-2

Unique Ingredient Identifier: DEH7Q6472O

Overview

Ladarixin is under investigation in clinical trial NCT04628481 (A Study of Oral Ladarixin in New-onset Type 1 Diabetes and a Low Residual Β-Cell Function).

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Ladarixin With Sotorasib in Advanced NSCLC - Phase II	2023/04/18	NCT05815186	Phase 2	Withdrawn	NYU Langone Health
Ladarixin With Sotorasib in Advanced NSCLC	2023/04/18	NCT05815173	Phase 1	Recruiting	NYU Langone Health
Clinical Trial on Ladarixin Adjunctive Therapy to Improve Glycemic Control in Type 1 Diabetes.	2022/05/10	NCT05368402	Phase 2	Terminated	Dompé Farmaceutici S.p.A
Ladarixin as Adjunctive Therapy to Improve Insulin Sensitivity and Glucometabolic Outcomes in Type 1 Diabetes	2021/09/05	NCT05035368	Phase 2	Withdrawn	Dompé Farmaceutici S.p.A
A Study to Assess Efficacy/Safety of Ladarixin in Type 1 Diabetes Patients With Preserved ß-cell Function at Baseline.	2021/05/24	NCT04899271	Phase 2	Terminated	Dompé Farmaceutici S.p.A
A Single Dose Study About the Influence of Food on the Oral Bioavailability of Ladarixin Capsule in Healthy Volunteers	2021/04/22	NCT04854642	Phase 1	Completed	Dompé Farmaceutici S.p.A
A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function	2020/11/13	NCT04628481	Phase 2	Active, not recruiting	Dompé Farmaceutici S.p.A
A Phase 2, Multicentre, Randomized, Double-blind, Placebo-controlled Study in Patients With New-onset Type 1 Diabetes	2016/06/28	NCT02814838	Phase 2	Completed	Dompé Farmaceutici S.p.A
Pilot Efficacy and Safety Study of Oral DF2156A in Patients With Active Bullous Pemphigoid	2012/04/05	NCT01571895	Phase 2	Terminated	Dompé Farmaceutici S.p.A
Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)	2008/06/16	NCT00697515	Phase 3	Completed	Shire

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Related News

No news found

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Product

Company

Legal

© 2025 MedPath, Inc. All rights reserved.